ArticleBMC cancer2026
Assessing the accuracy and applicability of the risk of malignancy index in predicting histopathological diagnoses of ovarian malignancy among patients at Saint Paul's Hospital Millennium Medical College in Addis Ababa, Ethiopia, in 2024.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is a significant global health concern, with high mortality rates and limited early detection methods. Accurate assessment of the risk of malignancy in ovarian tumors is crucial for guiding treatment decisions.
objectiveTo assess the accuracy and applicability of the Risk of Malignancy Index (RMI) in predicting histopathologic diagnoses of ovarian malignancy among patients at Saint Paul's Hospital Millennium Medical College in Addis Ababa, Ethiopia, 2024.
methodAn institution based a two-year retrospective cohort study (2022-2023) was conducted Data were collected from March to April 2024, including 230 cases through census sampling. Sensitivity and specificity analyses assessed the diagnostic performance of the Risk of Malignancy Index (RMI) against histopathology as the gold standard. Correlation analysis was done to evaluate the risk of malignancy with histopathology of ovarian tumor. Multivariate analysis used to evaluate the associated factors with Risk of malignancy index with significance set at p < 0.05.
resultThe risk of malignancy index has strong correlation (r = 0.701) with histopathology of ovarian tumour. The sensitivity, specificity, PPV, NPV and accuracy of risk of malignancy index in the current study were 86.4%, 78%, 76%, 87.6% and 81.7% respectively. Being at premenopausal stage [AOR = 0.05; 95%CI (0.002-0.98), serum CA125 ≤ 35 [AOR = 0.002; 95%CI (0.00-0.02)] and absence of solid area are in Ultrasound [AOR = 0.03; 95%CI (0.005-0.16)] were also significantly associated with accuracy of risk of malignancy index. CONCLUSION & RECOMMENDATION: The correlation between RMI and histopathology of ovarian tumors is found to be strong. The accuracy of RMI is 81.7% and reasonably good. The menopausal status, serum level of CA-125 and presence of solid echotexture during ultrasound examination are factors significantly associated with the accuracy of risk of malignancy index. Physicians shall better use the risk of malignancy index for diagnosing the ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.